



MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

SUCRALFATE

**YELLOW: RECOMMENDED FOR RESTRICTED USE - FOR GASTROENTEROLOGY
CONSULTANT INITIATION AND PRIMARY CARE CONTINUATION**

**RED - RECOMMENDED FOR RESTRICTED USE – PRESCRIBING by PALLIATIVE CARE
SPECIALISTS for topical haemostatic use in palliative care ONLY**

MSEMOC recommendation:

Sucralfate oral suspension is recommended for restricted use for the defined indications following gastroenterology consultant initiation:

- Duodenal and gastric ulcer, and chronic gastritis (licensed indication), following treatment failure with standard treatment options and persistent symptoms.
- Radiation proctitis (off-label indication).

Sucralfate oral suspension is suitable for primary care continuation following gastroenterology consultant initiation, with appropriate information provided by the hospital specialist.

Oral administration:

- Prescribe licensed sucralfate 1g/5ml oral suspension sugar free for duodenal and gastric ulcer, and chronic gastritis (licensed indication), following treatment failure with standard treatment options and persistent symptoms. Usual treatment period is 4 to 6 weeks, or up to 12 weeks in resistant cases.
- Sucralfate 1g/5ml oral suspension sugar free (Sigma Pharmaceuticals Plc) is a licensed product.
- **Do not prescribe unlicensed sucralfate liquid preparations - BLACK LIST, unlicensed and not recommended for prescribing.** Please ensure correct product selection on primary care clinical systems.
- **Do not prescribe sucralfate tablets - BLACK LIST, unlicensed and not recommended for prescribing.**

Rectal administration:

- Prescribe licensed sucralfate 1g/5ml oral suspension sugar free for rectal administration for radiation proctitis (off-label indication). Please follow specialist instructions for duration of use.
- The oral suspension can be used to prepare and administer a sucralfate enema.
- Appropriate equipment, including syringes and catheters for administration, to be supplied by secondary care.
- Patients should be able to self-administer and will be provided with a hospital information leaflet.
- Sucralfate 1g/5ml oral suspension sugar free (Sigma Pharmaceuticals plc) is a licensed product.
- **Do not prescribe sucralfate enemas - BLACK LIST, unlicensed and not recommended for prescribing.**

Sucralfate paste is recommended for restricted use for the defined indication in palliative care settings only by a palliative care specialist (no GP prescribing):

- Topical haemostatic use in palliative care patients

Notes:

Bezoar formation: following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying.



Please refer to the BNF for further information regarding directions for administration, cautions, interactions and side effects.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	<ul style="list-style-type: none">• MIMS online: mims.co.uk. Sucralfate: https://www.mims.co.uk/drugs/gastrointestinal-tract/peptic-ulcer-z-e-syndrome/sucralfate (accessed 16.02.2021)• Drug Tariff online (February 2021): nhsbsa.nhs.uk: https://www.nhsbsa.nhs.uk/sites/default/files/2021-01/Drug%20Tariff%20February%202021.pdf (accessed 17.02.2021)• BNF online: bnf.nice.org.uk. Sucralfate: https://bnf.nice.org.uk/drug/sucralfate.html, https://bnf.nice.org.uk/medicinal-forms/sucralfate.html (accessed 17.02.2021)• Summary of Product Characteristics for sucralfate 1g/5ml oral suspension-provided by Sigma Pharmaceuticals Plc 17.02.2021
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	May 2021; May 2021
Review Date	May 2026 or sooner if subject to any new updates nationally